Prognostic factors

Dermatologic Clinics

Volumn 20, Issue 4, 2002, Pages 647-658

  Rogers, Gary S ^a   Braun, Stephanie M ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; CANCER CLASSIFICATION; CANCER STAGING; CELL TYPE; GENDER; HUMAN; INFLAMMATION; LYMPH NODE METASTASIS; MELANOMA; MITOSIS RATE; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THICKNESS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BIOPSY, NEEDLE; FEMALE; HETEROZYGOTE; HUMANS; INFANT, NEWBORN; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036788416     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(02)00027-X     Document Type: Review

References (159)

1. Allen AC, Spitz S. Malignant melanoma: a clinico-pathological analysis of the criteria for diagnosis and prognosis. Cancer 1953;6:1-45.
2. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48.
3. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19: 3622-34.
4. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-91.
5. Ruiter DJ, Testori A, Eggermont AM, et al. The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group. Ann Oncol 2001;12:9-11.
6. Clark Jr. WH, From L, Bernardino EA, et al. The histogenesis and biological behavior of primary human malignant melanoma of the skin. Cancer Res 1969; 29:705-27.
7. Cascinelli N, Zurrida S, Galimberti V, et al. Acral lentiginous melanoma: a histological type without prognostic significance. J Dermatol Surg Oncol 1994;20:817-22.
8. McGovern VJ, Shaw HM, Milton GW, et al. Is malignant melanoma arising in a Hutchinson's melanotic freckle a separate disease entity? Histopathology 1980;4:235-42.
9. Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in Caucasians: clinical features, histopathology, and prognosis in 112 patients. Br J Dermatol 2000;143:275-80.
10. Urist MM, Balch CM, Soong S-J, et al. Head and neck melanoma in 534 clinical stage I patients: a prognostic factors analysis and results of surgical treatment. Ann Surg 1984;200:769-75.
11. Slingluff Jr. CL, Vollmer R, Seigler HF. Acral melanoma: a review of 185 patients with identification of prognostic variables. J Surg Oncol 1990;45:91-8.
12. Balch CM, Soong S-J, Murad TM, et al. A multi-factorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193:377-88.
13. Bevilacqua RG, Coit DG, Rogatko A, et al. Axillary dissection in melanoma: prognostic variables in node-positive patients. Ann Surg 1990;212:125-31.
14. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-5.
15. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes: a multivariate analysis. Ann Surg 1991;214:627-36.
16. Coit DG. Prognostic factors in patients with melanoma metastatic to regional lymph nodes. Surg Oncol Clin North Am 1992;1:281-95.
17. Day C, Sober AJ, Lew RA, et al. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional lymph nodes. Cancer 1981;47: 955-62.
18. Drepper H, Beiss B, Hofherr B, et al. The prognosis of patients with stage III melanoma. Cancer 1993;71: 1239-46.
19. Morton DL, Wanek L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional lymph nodes: analysis of prognostic factors in 1134 patients from John Wayne Cancer Clinic. Ann Surg 1991;214:491-9.
20. Slingluff Jr. CL, Vollmer R, Seigler HF. Stage II malignant melanoma: presentation of a prognostic model and assessment of specific active immunotherapy in 1,273 patients. J Surg Oncol 1988;39:139-47.
21. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current AJCC staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-51.
22. Breslow A. Problems in the measurement of tumor thickness and level of invasion in cutaneous melanoma. Hum Pathol 1977;8:1-2.
23. Breslow A. Tumor thickness in evaluating prognosis of cutaneous melanoma [letter]. Ann Surg 1978; 187:440.
24. Prade M, Sancho-Garnier H, Cesarini JP, et al. Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer 1980; 26:159-63.
25. Lock-Anderson J, Hou-Jensen K, Hansen JP, et al. Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Hand Surg 1995;29:141-8.
26. Breslon A. cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
27. Balch CM, Song S-J, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, editors. Cutaneous melanoma. 2nd edition. Philadelphia: Lippincott; 1992. p. 165-87.
28. Balch CM, Murad TM, Soong S-J, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978;188:732-42.
29. Balch CM, Soong S-J, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979;86:343-51.
30. Rogers GS, Kopf AW. Hazard-rate analysis in stage I melanoma. Arch Derm 1986;9(122):999-1002.
31. Slingluff Jr. CL, Vollmer RT, Reintgen DS, Seigler H. Lethal "thin" malignant melanoma: identifying patients at risk. Ann Surg 1988;208:150-61.
32. Kelly JW, Sagebiel RW, Clyman S, Blois MS. Thin level IV malignant melanoma: a subset in which level is the major prognostic indicator. Ann Surg 1985;202: 98-103.
33. Buttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma: optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995;75:2499-506.
34. Mansson-Brahme E, Carstensen J, Erhardt K, et al. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994;73:2324-32.
35. Marghoob AA, Koenig K, Bittencourt FV, et al. Breslow thickness and Clark level in melanoma: support for including level in pathology reports and in AJCC staging. Cancer 2000;88:589-95.
36. Morton DL, Davtyan DG, Wanek LA, et al. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993;71: 3737-43.
37. Finley JW, Gibbs JF, Rodriguez LM, et al. Pathologic and clinical features influencing outcome in thin cutaneous melanoma: correlation with newly proposed staging system. Ann Surg 2000;66(6):527-31.
38. Salman SM, Rogers GS. Prognostic factors in thin cutaneous malignant melanoma. J Dermatol Surg Oncol 1990;16:413-8.
39. Shaw HM, McCarthy WH, McCarthy SW, et al. Thin malignant melanomas and recurrence potential. Arch Surg 1987;122:1147-50.
40. Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 1975;182:572-5.
41. Averbook BJ, Russo LJ, Mansour EG. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 1998;124:746-56.
42. Shaw HM, Balch CM, Soong S-J, et al. Prognostic histopathologic factors in malignant melanoma. Pathology 1985;17:271-4.
43. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
44. Cascinelli N, Marubini E, Morabito A, et al. Prognostic factors for stage I melanoma of the skin: a review. Stat Med 1985;4:265-78.
45. Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000;89:453-62.
46. Balch CM, Soong S-J, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Ann Surg Oncol 2000;7:87-97.
47. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980;45:3012-7.
48. Balch CM, Soong S-J, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama and New South Wales, Australia. Ann Surg 1982;196:677-84.
49. Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1-to 4-mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-63.
50. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218(3):262-7.
51. McGovern VJ, Shaw HM, Milton GW, et al. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 1982;6:399-407.
52. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 1998;5:322-8.
53. Kim SH, Garcia C, Rodriguez J, et al. Prognosis of thick cutaneous melanoma. J Am Coll Surg 1999; 188:241-7.
54. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, et al. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous melanoma. Arch Dermatol 1998;134:983-7.
55. Masbeck A, Westerdahl J, Ingvar C, et al. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985: prognostic factors and histologic correlations. Cancer 1997;79:275-83.
56. Mackie RM, Aitchison T, Sirel JM, et al. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86 and their subsequent validation. Br J Cancer 1995;71:173-6.
57. Corona R, Mele A, Amini M, et al. Intraobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996;14:1218-23.
58. Greenstein DM, Rogers GS. Advances in the diagnosis and treatment of melanoma. Dermatol Surg Oncol 1991;21(11):919-26.
59. Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995;13: 2361-8.
60. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8:400-14.
61. Gershenwald JE, Prieto V, Colome-Grimmer MI, et al. The prognostic significance of microscopic tumor burden in 925 melanoma patients undergoing sentinel lymph node biopsy [abstract]. Proc Am Soc Clin Oncol 2000;19:15a.
62. Drepper H, Biess B, Hofherr B, et al. The prognosis of patients with stage III melanoma. Cancer 1993;71: 1239-46.
63. Cascinelli N, Vaglini M, Nana M, et al. Prognosis of skin melanoma with regional node metastases (stage II). Surg Oncol 1984;25:240-7.
64. Messaris GE, et al. Prognostic variables for patients with stage III malignant melanoma. Eur J Surg 2000; 166:233-9.
65. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000;7:469-74.
66. van der Velde-Zimmermann D, Schipper ME, de Weger RA, et al. Sentinel lymph node biopsies in melanoma patients: a protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol 2000;7:51-4.
67. van der Velde-Zimmermann D, Roijers JF, Bouwens-Rombouts A, et al. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996;149:759-64.
68. Shivers SC, Xiangning W, Weiguo L, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410-5.
69. Harrist TJ, Rigel DS, Day Jr. CL, Sober AJ, Lew RA, Rhodes AR, et al. Microscopic satellites" are more highly associated with regional lymph nodes metastases than is primary melanoma thickness. Cancer 1984;53:2183-7.
70. Balch CM, et al. A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1982; 1:126-33.
71. Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782-93.
72. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;181:193-201.
73. Deichmann M, Benner A, Bock M, et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17:1891-6.
74. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998;16:1103-11.
75. Franzke A, Probst-Kepper M, Buer J, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule I and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998;78:40-5.
76. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921-9.
77. Sirott M, Bajorin D, Wong G, et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993;72:3091-8.
78. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
79. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the ECOG Trial EST1684. J Clin Oncol 1996;14:7-17.
80. Presant CA, Bartolucci AA and the Southeastern Cancer Study Group. Prognostic factors in malignant melanoma. The Southeastern Cancer Study Group Experience. Cancer 1982;49:2192-6.
81. Einhorn LH, Burgess MA, Vallejos C, et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 1974;34: 1995-2004.
82. Amer MH, Al-Sarraf M, Vaitkevicius VK. Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 1979;149:687-92.
83. Rogers GS. Treatment of stage I melanoma: surgical and adjuvant therapy. In: Arndt KA, Robinson JK, LeBeoit RM, editors. Cutaneous Medicine and Surgery. Philadelphia (PA): WB Saunders Co.; 1995; p. 1576-601.
84. Clark WH. The histogenesis and biologic behavior of primary malignant melanomas of the skin. Cancer Res 1969;29(3):705-9.
85. Colloby PS, West KP, Fletcher A. Observer variation in the measurement of Breslow depth and Clark's level in thin cutaneous malignant melanoma. J Pathol 1991;163:245-50.
86. Bachaud J-M, Shubinski R, Boussin G, et al. Stage I cutaneous malignant melanoma: risk factors of loco-regional recurrence after wide local excision and clinical perspectives. Eur J Surg Oncol 1992;18: 442-8.
87. Clark WH, Elder DE, Guerry D, et al. Model for predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
88. Day CL, Mihm MC, Sober AJ. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness: an appraisal of 'thin' level IV lesions. Ann Surg 1982;195:30-4.
89. Day CL, Lew RA, Mihm MC, Sober AJ. A multi-variate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness: the importance of revealing alternative Cox Models. Ann Surg 1982;195:44-9.
90. Day CL, Mihm MC, Sober AJ. Predictors in late deaths among patients with clinical stage I melanoma who have not had bony or visceral metases within the first 5 years after diagnoses. J Am Acad Dermatopathol 1983;8:864-8.
91. Gamel JW, George SL, Staley WE, Seigler HF. Skin melanoma: cured traction and survival time as functions of thickness, site histologic, type, age and sex. Cancer 1993;72:1219-33.
92. Hacene K, Le Doussal VL, Brunet M, et al. Prognostic index for clinical stage I cutaneous malignant melanoma. Cancer Res 1983;43:2291-6.
93. Songegaard K, Schou G. Therapeutic and clinical-pathological factors in the survival of 1,469 patients with primary cutaneous malignant melanoma in clinical stage I: a multivariate regression analysis. Virchows Arch 1985;408:249-58.
94. Soong S-J. A computerized mathematical and scoring systems for predicting outcome in patients with localized melanoma. In: Balch CM, Houghton AN, Milton GW, et al, editors. Cutaneous melanoma. Philadelphia: JB Lippincott; 1992. p. 200-12.
95. Stidham K, Johnson JL, Seigler HF. Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 1994;129: 316-24.
96. Thorn M, Ponten F, Bergstrom R, et al. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86: 761-9.
97. Vossaert KA, Silverman MK, Kopf AW, et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 1992; 26:429-40.
98. Reintgen DS, Vollmer R, Tso CY, Seigler HF. Prognosis for recurrent stage I malignant melanoma. Arch Surg 1987;122:1338-42.
99. Shumante CR, Carlson GW, Giacco GG, et al. The prognostic implications of location for scalp melanoma. Am J Surg 1991;162:315-9.
100. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol 1978;114: 871-3.
101. Reintgen DS, Paull DE, Seigler HF, et al. Sex related survival differences in instances of melanoma. Surgery 1984;159:367-72.
102. Meyskens FL, Berdeaux DH, Parks B, et al. Cutaneous malignant melanoma (Arizona Cancer Center Experience) I: Natural history and prognostic factors influencing survival in patients with Stage I disease. Cancer 1988;62:1207-14.
103. O'Doherty CJ, Precott RJ, White H, et al. Sex differences in presentation of cutaneous malignant melanoma and in survival from stage I disease. Cancer 1986;58:788-92.
104. Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in stage I invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg 1991;78:1108-10.
105. Sahin S, Rao B, Kopf AW, et al. Predicting ten-year survival of patients with primary cutanoeus melanoma: corroboration of a prognostic model. Cancer 1997;80:1426-31.
106. Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994;1:487-94.
107. Cohen HJ, Cox E, Manton K, et al. Malignant melanoma in the elderly. J Clin Oncol 1987;5:100-6.
108. Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994;1:487-94.
109. Loggie B, Ronan SG, Bean J, et al. Invasive cutaneous melanoma in elderly patients. Arch Dermatol 1991;127:1188-93.
110. Shaw HM, McGovern VJ, Milton GW, et al. The female superiority in survival in clinical stage II cutaneous malignant melanoma. Cancer 1982;49:1941-4.
111. Wanek LA, Elashoff RM, Goradia TM, et al. Application of multistage Markov modeling to malignant melanoma progression. Cancer 1994;73:336-43.
112. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol 1969;97:459-68.
113. Leon P, Daly JM, Synnestvedt M, et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991; 126:1461-8.
114. Vollmer RT. Malignant melanoma: a multivariate analysis of prognostic factors. Pathol Annu 1989; 24:383-407.
115. Kopf AW, Gross DF, Rogers GS, et al. Prognostic index for malignant melanoma. Cancer 1987;59: 1236-41.
116. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immuno therapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine; overall results of a randomized trial of the Southwest Oncology Group. Journal of Clinical Oncology 2002;20(8):2058-66.
117. Brocker E-V, Kolde G, Steinaussen D, et al. The pattern of the mononuclear infiltrate as a prognostic parameter in flat superficial spreading melanomas. J Cancer Res Clin Oncol 1984;107:48-52.
118. Day CL, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the trunk: location near the midline is not an independent risk factor for recurrent disease. Am J Surg 1981;142:247-51.
119. Hansen MG, McCarten AB. Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck. Am J Surg 1974;128:557-61.
120. Day CL, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the lower extremity. Surgery 1981;89:599-603.
121. Day CL, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the upper extremity: the importance of anatomic subsites in predicting recurrent disease. Ann Surg 1981;193:436-40.
122. Sober AJ, Day CL, Fitzpatrick TB, et al. Early death from clinical stage I melanoma. J Invest Dermatol 1983;80:53s-5s.
123. Sober AJ, Day CL, Fitzpatrick TB, et al. Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients. J Invest Dermatol 1983;80:53s-5s.
124. Mascaro JM, Molgo M, Castel T, Castro J. Plasma cells within the infiltrate of primary cutaneous malignant melanoma of the skin: a confirmation of its histoprognostic value. Am J Dermatopathol 1987;9: 497-9.
125. Brocker EB, Zwadlo G, Suter L, Brune M, Sorg C. Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol Immunother 1987;25:81-6.
126. Brogelli L, Umberto MR, Moretti S, Urso C. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res 1992;2:87-9.
127. Cooper PH, Wanebo HJ, Hagar W. Regression in thin malignant melanoma. Arch Dermatol 1985;121: 1127-31.
128. Kelly JW, Sagebeil RW, Blois MS. Regression in malignant melanoma: a histologic feature without independent prognostic significance. Cancer 1985;56: 2287-91.
129. Trau H, Kopf AW, Rigel DS, et al. Regression in malignant melanoma. J Am Acad Dermatol 1983;8: 363-8.
130. Wanebo HJ, Cooper PH, Hagar RW. Thin (<1 mm) melanomas of the upper extremities are biologically favorable lesions not influenced by regression. Ann Surg 1985;201:499-504.
131. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 1978;42:2282-92.
132. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanoma with regression and metastases. Arch Dermatol 1987;123: 1326-30.
133. Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutanoeus malignant melanomas clinical Stage 1. Virchows Arch 1985;408:241-7.
134. Paladugu RR, Yonemoto RH. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg 1983;118:41-4.
135. Woods JE, Soule EH, Creagan ET. Metastasis and death in patients with thin malignant melanoma (less than 0.76mm). Ann Surg 1983;198:63-4.
136. Koh HK, Michalik E, Sober AJ, Lew RA, Day CL, Clark W, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol 1984;2:994-1001.
137. Kopf AW, et al. Thickness of malignant melanoma: global analysis of related factors. J Dermatol Surg Oncol 1987;13:345.
138. Heenan PJ, English DR, Holman CD, Armstrong BK. Survival among patients with clinical stage I cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 and 1980/1981. Cancer 1991;68: 2079-87.
139. Day CL, et al. Classification of malignant melanoma according to histologic morphology of melanoma nodules. J Dermatol Surg Oncol 1982;8:874.
140. Fallowfield ME, Cook MG. Vascular invasion in malignant melanomas: an independent prognostic variable? Am J Surg Pathol 1989;13:217-20.
141. Langley R, Barnhill R, Mihm MC, et al. Neoplasms: cutaneous melanoma. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Dermatology in general medicine. 5th edition. New York: McGraw-Hill; 1999. p. 1080-116.
142. Bieligk SC, Ghossein R, Bhattacharya S, et al. Detection of tyrosinase mRNA by reverse transcriptasepolymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol 1999;6:232-40.
143. Blaheta HJ, Schittek B, Breuninger H, et al. Detection of melanoma micrometastasis in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999;23:822-8.
144. Goydos JS, Ravikumar TS, Germino FJ, et al. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-I and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 1998;187:182-90.
145. Wang X, Heller R, Van Voorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-74.
146. Sarantou T, Chi DDJ, Garrison DA, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer 1997;57:1371-6.
147. Curry BJ, Myers K, Hersey P. Utility of tests for circulating melanoma cells in identifying patients who develop recurrent melanoma. Recent Results Cancer Res 2001;158:211-30.
148. Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000;60:2253-7.
149. Runnels LW, Yue L, Claphan DE. TRP-PLIK, a bifunctional protein with kinase and ion channel activities. Science 2001;291:1043-7.
150. Deeds J, Cronin FE, Duncan LM. Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol 2000;31:1346-56.
151. Duncan LM, Deeds J, Hunter J, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastases. Cancer Res 1998; 58:1515-20.
152. Duncan LM, Deeds J, Cronin FE, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001;19:568-76.
153. Niezabitowski A, et al. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 1999;70: 150-60.
154. Vecchiato A, Rossi CR, Montesco MC, et al. Proliferating cell nuclear antigen (PCNA) and recurrence in patients with cutaneous melanoma. Melanoma Res 1994;4:207-11.
155. Smolle J, Hofmann-Wellenhof R, Kerl H. Prognostic significance of proliferation and motility in primary malignant melanoma of the skin. J Cutan Pathol 1992;19:110-5.
156. Soyer HP. Ki 67 immunostaining in melanocytic skin tumors: correlation with histologic parameters. J Cutan Pathol 1991;18:264-72.
157. Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-I proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995;105:22-6.
158. Vilmer C, Bailey C, Le Doussal V, et al. Thin melanomas with unusual aggressive behavior: a report on nine cases. Melanoma Group of French Federation of Cancer Centers. J Am Acad Dermatol 1996;34: 439-44.
159. Thorn M, Adami HO, Ringborg U, et al. The association between anatomic site and survival in melanoma: an analysis of 12,353 cases from the Swedish Cancer Registry. Eur J Cancer Clin Oncol 1989;25:483-91.